Long

AEZS European approval to market Macrillen

AEterna has a variety of new products in its pipeline.
Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency.

AEterna received European approval to market Macrillen.

Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition.”

I think AEZS is a sleeping giant.

My price target is $1.25.

Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.